Stay updated on Niraparib & Cabozantinib in Advanced Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib & Cabozantinib in Advanced Urothelial Cancer Clinical Trial page.

Latest updates to the Niraparib & Cabozantinib in Advanced Urothelial Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a Locations section with a Catalonia subsection and updated the page revision to v3.3.3. Removed the separate Catalonia Locations grouping and the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; this appears to be a minor system update and does not alter core study details, eligibility, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe generic government funding notice at the top of the page was removed.SummaryDifference0.4%

- Check63 days agoChange DetectedScreenshots show only minor text and layout adjustments on the study page, with no changes to core content, eligibility, outcomes, or contact information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check91 days agoChange DetectedNew operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.SummaryDifference2%

- Check98 days agoChange DetectedPage version updated from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.0%

Stay in the know with updates to Niraparib & Cabozantinib in Advanced Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib & Cabozantinib in Advanced Urothelial Cancer Clinical Trial page.